Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers

Journal of the Canadian Urological Association

Volumn 11, Issue 3-4April, 2017, Pages E138-E142

  Gandhi, Shreyas ^a   Vasisth, Gaurav ^b   Kapoor, Anil ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018320278     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.4371     Document Type: Review

References (26)

1. Cridge BJ, Rosengren RJ. Critical appraisal of the potential use of cannabinoids in cancer management. Cancer Manag Res 2013;3:301-13.
2. Gurney J, Shaw C, Stanley J, et al. Cannabis exposure and risk of testicular cancer: A systematic review and meta-analysis. BMC Cancer 2015;15:897. https://doi.org/10.1186/s12885-015-1905-6
3. Larrinaga G, Sanz B, Blanco L, et al. Cannabinoid CB1 receptor is expressed in chromophobe renal cell carcinoma and renal oncocytoma. Clin Biochem 2013;46:638-41. https://doi.org/10.1016/j. clinbiochem.2012.12.023
4. Daling JR, Doody DR, Sun X, et al. Association of marijuana use and the incidence of testicular germ cell tumours. Cancer 2009;115:1215-23. https://doi.org/10.1002/cncr.24159
5. Sarfaraz S, Afaq F, Adhami VM, et al. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 2005;65:1635-41. https://doi.org/10.1158/0008-5472.CAN-04-3410
6. Sarfaraz S, Adhami VM, Syed DN, et al. Cannabinoids for cancer treatment: Progress and promise. Cancer Res 2008;68:339-42. https://doi.org/10.1158/0008-5472.CAN-07-2785
7. Diaz-Laviada I. The endocannabinoid system in prostate cancer. Nat Rev Urol 2011;8:553-61. https://doi.org/10.1038/nrurol.2011.130
8. Guzman M, Duarte MJ, Blazquez C, et al. A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 2006;95:197-203. https://doi.org/10.1038/sj.bjc.6603236
9. Larrinaga G, Varona A, Perez I, et al. Expression of cannabinoid receptors in human kidney. Histol Histopathol 2010;25:1133-8.
10. Wang D, Wang H, Ning W, et al. Loss of cannabinoid receptor 1 accelerates intestinal tumour growth. Cancer Res 2008;68:6468-76. https://doi.org/10.1158/0008-5472.CAN-08-0896
11. Larrinaga G, Sanz B, Perez I, et al. Cannabinoid CB1receptor is downregulated in clear-cell renal cell carcinoma. J Histochem Cytochem 2010;58:1129-34. https://doi.org/10.1369/jhc.2010.957126
12. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases. Am J Surg Pathol 2002;26:281-91. https://doi.org/10.1097/00000478-200203000-00001
13. Orellana-Serradell O, Poblete CE, Sanchez C, et al. Proapoptotic effect of endocannabinoids in prostate cancer cells. Oncol Rep 2015;33:1599-1608. https://doi.org/10.3892/or.2015.3746
14. Sreevalsan S, Joseph S, Jutooru I, et al. Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent. Anticancer Res 2011;31:3799-807.
15. Olea-Herrero N, Vara D, Malagarie-Cazenave S, et al. The cannabinoid R+ methanandamide induces IL-6 secretion by prostate cancer PC3 cells. J Immunotoxicol 2009;6:249-56. https://doi.org/10.3109/15476910903241696
16. Chung SC, Hammarsten P, Josefsson A, et al. A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer 2009;45:174-82. https://doi.org/10.1016/j.ejca.2008.10.010
17. Thors L, Bergh A, Persson E, et al. Fatty acid amide hydrolase in prostate cancer: Association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. PLoS One 2010;5:e12275. https://doi.org/10.1371/journal.pone.0012275
18. Gasperi V, Evangelista D, Oddi S, et al. Regulation of inflammation and proliferation of human bladder carcinoma cells by type-1 and type-2 cannabinoid receptors. Life Sci 2015;138:41-51. https://doi.org/10.1016/j.lfs.2014.09.031
19. Moussa M, Omran Z, Nosseir M, et al. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma. APMIS 2009;117:45-52. https://doi.org/10.1111/j.1600-0463.2008.00014.x
20. Yang H, Gu J, Lin X, et al. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res 2008;14:2236-44. https://doi.org/10.1158/1078-0432.CCR-07-1670
21. Lacson JC, Caroll JD, Tuazon E, et al. Population-based case-control study of recreational drug use and testis cancer risk confirms association between marijuana use and non-seminoma risk. Cancer 2012;118:5374-83. https://doi.org/10.1002/cncr.27554
22. Trabert B, Sigurdson AJ, Sweeney AM, et al. Cancer 2011;117:848-53. https://doi.org/10.1002/cncr.25499
23. Skeldon SC, Goldenberg SL. Uurological complications of illicit drug use. Nat Rev Urol 2014;11:169-77. https://doi.org/10.1038/nrurol.2014.22
24. Patcher P. Towards the use of non-psychoactive cannabinoids for prostate cancer. Br J Pharmacol 2013;168:76-8. https://doi.org/10.1111/j.1476-5381.2012.02121.x
25. Maida V, Dauninck PJ. A user’s guide to cannabinoid therapies in oncology. Curr Oncol 2016;23:398-406. https://doi.org/10.3747/co.23.3487
26. Velasco G, Sanchez C, Guzman M. Anticancer mechanisms of cannabinoids. Curr Oncol 2016;23:S23-32.